Kilitch Drugs logo

Kilitch Drugs

KILITCH NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹629 Cr
Volatility
Moderate
P/E Ratio
21.65
EBITDA
₹47.80 Cr
Return on Equity
10.66%
Debt to Equity
0.32
Book Value
₹79.99
52W High
₹439
52W Low
₹117.25

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

2
  • Company has delivered good profit growth of 54.7% CAGR over last 5 years
  • Company's median sales growth is 28.4% of last 10 years

Weaknesses

4
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 10.2% over last 3 years.
  • Company has high debtors of 186 days.
  • Promoter holding has decreased over last 3 years: -4.47%

Growth Rate

Revenue Growth
17.76% lower than 3Y
Net Income Growth
18.47% lower than 3Y
Cash Flow Change
36.6%
ROE
-14.31% lower than 3Y
ROCE
-23.99% lower than 3Y
EBITDA Margin (Avg.)
-4.72% lower than 3Y

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
36.56
41.2
31.79
44.82
33.45
47.47
56.17
61.23
43.14
48.92
53.81
89.6
44.88
Expenses
30.38
32.58
29.51
37.74
31.79
41.37
47.44
46.64
39.88
43.88
47.66
67.46
41.94
Operating Profit
6.18
8.62
2.28
7.08
1.66
6.1
8.73
14.59
3.26
5.04
6.15
22.14
2.94
OPM %
16.9%
20.92%
7.17%
15.8%
4.96%
12.85%
15.54%
23.83%
7.56%
10.3%
11.43%
24.71%
6.55%
Other Income
0.56
0.49
2.96
0.47
2.57
5.16
1.73
1.7
2.56
6.66
1.53
0.49
2.9
Interest
1.5
1.51
1.6
1.32
1.73
0.31
1.4
1.6
1.53
1.44
1.15
1.44
0.88
Depreciation
0.71
0.82
0.81
0.93
0.85
0.61
0.81
0.85
0.84
0.86
0.94
0.98
1.09
PBT
4.53
6.78
2.83
5.3
1.65
10.34
8.25
13.84
3.45
9.4
5.59
20.21
3.87
Tax %
32.67%
24.93%
38.16%
30.57%
93.33%
16.73%
32%
26.23%
34.49%
14.47%
22.9%
26.37%
48.84%
Net Profit
3.06
5.09
1.74
3.68
0.11
8.61
5.61
10.22
2.27
8.04
4.31
14.88
1.96
EPS in Rs
0.99
1.35
0.83
1.03
0.38
2.46
1.7
2.97
0.87
2.34
1.27
4.15
0.83
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
19
21
27
51
82
53
68
114
140
154
198
235
237
Expenses
21
25
28
45
75
53
63
104
122
130
167
198
201
Operating Profit
-2
-4
-1
6
7
0
5
10
18
24
32
37
36
OPM %
-9%
-19%
-2%
11%
9%
0.8%
8%
9%
13%
16%
16%
16%
15%
Other Income
3
2
1
3
4
4
3
3
3
4
11
11
12
Interest
0
0
0
0
1
1
1
1
5
6
5
6
5
Depreciation
2
10
10
2
2
2
2
2
4
3
3
4
4
PBT
-1
-12
-9
6
9
2
5
10
12
19
34
39
39
Tax %
-70%
-4%
-5%
16%
55%
48%
27%
35%
31%
30%
28%
24%
—
Net Profit
0
-11
-9
5
4
1
4
6
8
14
25
30
29
EPS in Rs
-0.1
-3.89
-3.09
1.72
1.15
0.25
1.09
2.17
3.08
4.17
7.63
8.63
8.59
Div. Payout %
0%
0%
0%
13%
20%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
13
13
13
14
15
15
15
16
16
16
16
35
Reserves
107
95
88
98
106
103
112
124
136
160
186
245
Borrowings
0
0
1
1
9
13
15
20
22
32
49
89
Other Liabilities
7
8
11
15
13
12
61
50
46
32
61
89
Total Liabilities
127
117
113
128
144
143
203
210
220
240
313
458
Fixed Assets
9
42
33
33
32
32
30
65
64
62
64
67
CWIP
0
0
1
3
20
30
65
3
4
6
47
140
Investments
72
49
53
56
53
52
60
71
62
72
72
75
Other Assets
46
25
26
35
38
30
47
71
90
100
129
176
Total Assets
127
117
113
128
144
143
203
210
220
240
313
458
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-8
17
1
1
0
4
46
6
3
-2
18
24
Investing
-31
-20
-2
-4
-14
-10
-38
-15
8
-8
-40
-100
Financing
0
0
0
6
17
1
2
7
-1
9
13
82
Net Cash Flow
-39
-2
0
2
3
-5
10
-2
10
-1
-9
6
Free Cash Flow
-10
-26
0
-2
-19
-6
9
-2
-1
-8
-29
-76
CFO/OP
430
-442
-202
25
60
1,598
877
79
39
23
82
92
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
243
286
196
148
86
109
122
132
142
149
156
186
Inventory Days
124
110
84
39
36
70
35
28
10
18
53
33
Days Payable
124
154
184
108
33
89
525
239
200
118
189
230
Cash Conversion Cycle
243
241
96
79
89
89
-367
-79
-48
50
20
-11
Working Capital Days
197
234
115
93
37
22
-223
-40
-4
30
56
49
ROCE %
—
-10%
-9%
5%
6%
1%
3%
6%
10%
13%
16%
13%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Kilitch Drugs insights

66 extracted metrics + investor summaries across FY11–FY26.

Log in — free

Shareholding Pattern

FIIs0.12%Promot.63.77%Others6.47%Public29.64%As ofJun 2026

Documents

Frequently Asked Questions about Kilitch Drugs

What does Kilitch Drugs (India) Ltd do?
Incorporated in 1978, Kilitch Drugs Ltd is engaged in the operation and management of Pharmaceutical Products[1]
Where is Kilitch Drugs (India) Ltd (KILITCH) listed?
Kilitch Drugs (India) Ltd trades as KILITCH on the NSE and under code 524500 on the BSE.
Which sector does Kilitch Drugs (India) Ltd belong to?
Kilitch Drugs (India) Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Kilitch Drugs (India) Ltd?
Kilitch Drugs (India) Ltd has a market capitalisation of ₹629.31 Cr, which places it in the Small Cap band.
What is the PE ratio of Kilitch Drugs (India) Ltd?
Kilitch Drugs (India) Ltd trades at a PE ratio of 21.65, against a book value of ₹79.99 per share.
What is the 52-week high and low of Kilitch Drugs (India) Ltd?
Over the last 52 weeks Kilitch Drugs (India) Ltd has traded between ₹117.25 and ₹439.
What is the Return on Equity (ROE) of Kilitch Drugs (India) Ltd?
Kilitch Drugs (India) Ltd reported a return on equity of 10.66%. Its debt-to-equity ratio is 0.32.

Company Information

Incorporated in 1978, Kilitch Drugs Ltd is engaged in the operation and management of Pharmaceutical Products[1]

Website kilitch.com
CEO Mr. Mukund Prataprai Mehta B.Com., LL.B.
Employees 187
Listed 2002-03-05
Face Value ₹ 10
Issued Size 1,74,80,782

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/KILITCH.md for Kilitch Drugs (India) Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List